Amicus Therapeutics (FOLD) : 7 Wall Street analysts covering Amicus Therapeutics (FOLD) believe that the average level the stock could reach for the short term is $14. The maximum price target given is $19 and the minimum target for short term is around $9, hence the standard deviation is calculated at $3.83.
The short interest in Amicus Therapeutics (FOLD) has increased from 21,075,941 on June 15,2016 to 22,154,338 on June 30,2016. The change was measured at 1,078,397 shares or 5.1%. The leftover shorts were 18.4% of the floated shares. The days to cover are 9, given the average daily volume of 2,529,282 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD). The shares have now been rated Buy by the stock experts at the ratings house. Bank of America announces the current price target of $10 per share on Amicus Therapeutics . The rating by the firm was issued on May 18, 2016.
Amicus Therapeutics (NASDAQ:FOLD): On Thursdays trading session , Opening price of the stock was $5.88 with an intraday high of $5.93. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $5.66. However, the stock managed to close at $5.69, a loss of 1.73% for the day. On the previous day, the stock had closed at $5.79. The total traded volume of the day was 3,274,788 shares.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.